Skip to main content
Home

Primary Menu

  • OUR STRATEGY
    • WHAT SETS US APART
    • OUR HISTORY
    • OUR LEADERSHIP
    • FAQ
  • OUR IMPACT
    • WHAT WE SUPPORT
    • CURRENT PROJECTS
    • TIMELINE
  • GET INVOLVED
    • WAYS TO DONATE
    • BECOME A SPONSOR
    • LEGACY PLANNING
    • FUNDRAISE
    • CORPORATE PARTNERS
  • FOR SCIENTISTS
    • AWARD PROGRAMS
    • APPLICATION GUIDELINES
    • GENERATIONS OF INNOVATORS
    • SELECTION COMMITTEES
    • ACCELERATING CANCER CURES
    • FAQ
  • NEWS
  • BROADWAY TICKETS
  • burger-menu
Search
search-button-x

Donate

  • DONATE

Damon Runyon News

View New Articles By

News

New Discoveries December 3, 2021
Investigating the impact of diet on tumor growth

Matthew G. Vander Heiden, MD, PhD, former Damon Runyon Innovator and current mentor, says he gets a lot of questions from his cancer patients about how their diet might impact disease progression. Often, these patients have heard the hypothesis that an aggressively calorie-restricted diet or the low-carbohydrate, high-fat ketogenic diet may slow tumor growth. The logic for these diets is that cancer cells require high levels of glucose to fuel their rapid proliferation, so depriving them of sugar might throw a wrench in the works. However, as Damon Runyon Fellow Evan C. Lien, PhD, a postdoc in Dr. Vander Heiden’s lab at MIT, put it: “A lot of the advice out there isn’t necessarily based on very good science.”

Read More
New Discoveries December 1, 2021
Demystifying the process of DNA repair

Like a leaky gas pipe in an apartment building, failure to repair DNA damage can have disastrous consequences, including the introduction of cancer-causing mutations. This is why our cells have complex mechanisms for recognizing and repairing broken DNA strands before too much damage has been done. In a big-picture sense, we know how DNA repair works: proteins responsible for sensing damage activate a cascade of other proteins, depending on the nature and location of the problem. But a granular understanding of this process, including which genes are involved, continues to elude scientists.

Read More
New Discoveries December 1, 2021
Using machine learning to predict prostate cancer behavior

Prostate cancer is among the most common cancers in American men, accounting for one in five new cancer diagnoses. Hormone therapy is currently the standard of care for patients with metastatic disease, but nearly all patients develop resistance to this treatment eventually. Extensive effort has therefore been directed toward the search for new drug targets, illuminating the biological underpinnings of the disease. Given a tumor sample from a patient with prostate cancer, researchers can now identify millions of genetic and molecular features, from single DNA mutations to RNA transcription errors to mutant protein complexes.

Read More
New Discoveries November 23, 2021
A better treatment approach for “atypical” lung cancers

Epidermal growth factor receptor (EGFR) is a protein on the surface of cells that receives signals telling the cell to grow. Mutations in the EGFR gene are known to drive a number of cancers, including non-small cell lung cancer. For patients with common EGFR mutations, known as “classical mutations,” EGFR inhibitor treatments are available and effective. But such targeted therapies have not been developed for patients with atypical mutations, often leaving chemotherapy as the only treatment option.

Read More
New Discoveries November 16, 2021
Damon Runyon Fellow Tyler Starr, PhD, named 2021 STAT Wunderkind

We are delighted to announce that Damon Runyon-HHMI Fellow Tyler Starr, PhD, of Fred Hutchinson Cancer Research Center, has been named a 2021 STAT Wunderkind. This award, granted annually to “the best early-career researchers in health and medicine in North America,” recognizes Tyler’s exceptional promise in the study of viruses and our immune systems.

Read More
New Discoveries November 10, 2021
New role discovered for mutant protein found in most breast cancers

Breast cancer is the most common cancer diagnosed in women worldwide, and an estrogen receptor known as ERα plays a critical role in more than 70% of these cancers. In healthy cells, when bound to estrogen, ERα activates a signaling pathway that controls cell growth, proliferation, and survival. In breast cancer, an abnormal variant of ERα sends this pathway into overdrive. For patients with ERα-positive breast cancer, estrogen-blocking hormone therapies like tamoxifen can prolong survival. Up to half of these patients will acquire resistance, however, creating an urgent need for novel treatment strategies targeting ERα.

Read More
New Discoveries October 28, 2021
Using genome sequencing to predict treatment response in blood cancer

Myeloproliferative neoplasms (MPNs) are cancers that arise when a mutated blood stem cell begins to produce too many red blood cells, white blood cells, or platelets. A number of mutations can drive MPNs, and studies have demonstrated that different mutations result in different clinical outcomes. For example, between the two most commonly mutated genes, JAK2 and CALR, JAK2-mutated MPNs tend to be the more aggressive cancers.

Read More
New Discoveries September 28, 2021
Single-cell sequencing sheds light on prostate cancer genome

As cancer cells evolve in response to treatment or other environmental pressures, a patient may end up with a highly diverse population of cancer cells circulating throughout their body. In these cases, a single biopsy from the tissue where the cancer originated is not enough to fully understand the cancer’s genome or how best to target it. Liquid biopsies are thus increasingly used to study circulating tumor cells (CTCs) in the blood, with single-cell CTC sequencing emerging as the next step in unraveling the mysteries of disease progression and treatment response.

Read More
New Discoveries September 28, 2021
Discovering how an enzyme needed for tumor growth is made

Sometimes, while investigating one question, scientists learn the answer to an entirely different one. Some of the most significant medical breakthroughs have begun with open-ended curiosity: insulin, for example, was discovered after two German doctors removed a dog’s pancreas in 1890 to better understand its role in digestion.

Read More
New Discoveries September 8, 2021
How pancreatic cancer rewires the cell’s metabolism to produce more energy

Because cancer cells proliferate at a higher rate than normal cells, they require more energy than normal cells, and thus need to rewire the cell’s energy-producing processes to meet this excessive demand. Think of spoiled Veruca Salt in Charlie and the Chocolate Factory rerouting the chocolate bar supply directly to her father’s factory, where his workers unwrapped them faster than any normal child could, expediting her discovery of a Golden Ticket.

Read More

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • …
  • Next page Next ›
  • Last page Last »

ABOUT

Annual Reports + Report Cards
Financial Overview
Our Team

CONNECT

1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006

Damon Runyon Cancer Research Foundation on Facebook Damon Runyon Cancer Research Foundation on LinkedIn Damon Runyon Cancer Research Foundation on BlueSky Damon Runyon Cancer Research Foundation on Instagram Damon Runyon Cancer Research Foundation on Youtube

    

© COPYRIGHT DAMON RUNYON. ALL RIGHTS RESERVED

PRIVACY POLICY